Stock Analysis

HEG Third Quarter 2025 Earnings: EPS: ₹4.32 (vs ₹2.26 in 3Q 2024)

NSEI:HEG
Source: Shutterstock

HEG (NSE:HEG) Third Quarter 2025 Results

Key Financial Results

  • Revenue: ₹5.90b (up 4.9% from 3Q 2024).
  • Net income: ₹834.0m (up 91% from 3Q 2024).
  • Profit margin: 14% (up from 7.8% in 3Q 2024).
  • EPS: ₹4.32 (up from ₹2.26 in 3Q 2024).
earnings-and-revenue-growth
NSEI:HEG Earnings and Revenue Growth February 13th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

HEG Earnings Insights

Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Electrical industry in India.

Performance of the Indian Electrical industry.

The company's shares are down 8.5% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 4 warning signs for HEG that you should be aware of.

Valuation is complex, but we're here to simplify it.

Discover if HEG might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NSEI:HEG

HEG

Manufactures and sells graphite electrodes in India and internationally.

Flawless balance sheet with high growth potential and pays a dividend.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.11% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|23.535% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|1.7389999999999999% overvalued
Jonataninho
Jonataninho
Community Contributor